Veraxa Biotech (VRXA) Director Warren Hosseinion Buys 6,024 Shares

What Happened Warren Hosseinion, a director of Veraxa Biotech AG (VRXA), purchased 6,024 ordinary shares on September 10, 2026 at $1.67 per share, for a reported total of $10,060. The transaction is coded "P" (purchase) in the filing, indicating an acquisition rather than a sale.

Key Details

• Transaction date: 2026-09-10; Price: $1.67 per share; Shares acquired: 6,024; Reported value: $10,060.
• Transaction code: P = Purchase (open-market or private purchase per the Form 4).
• Shares owned after the transaction: Not specified in the filing.
• Footnote F1: The filing notes the forfeiture of 71,332 ordinary shares (par value CHF 1/113.25) for no additional consideration in connection with the company’s business combination on June 10, 2026.
• Filing timeliness: Report filed 2026-09-29 for a 2026-09-10 transaction (late filing). Late Form 4s reduce timely transparency and can carry regulatory attention.

Context This is a small-dollar insider purchase (~$10k) by a director, which is a direct acquisition of company stock. Purchases can be more informative than routine sales, but the modest size and the late filing limit how much weight to place on this single transaction. The noted forfeiture from the June 10, 2026 business combination affected prior holdings and is disclosed in the footnote.